Norfolk

Researchers are evaluating the real-world experience of participants treated with BRIUMVI4 (ublituximab-xiiy) for relapsing multiple sclerosis (RMS). The study aims to assess the safety, effectiveness, and overall treatment experience of this medication in everyday clinical practice. The trial is observational, focusing on patients who have been prescribed BRIUMVI and tracking their outcomes over time. Participants in this study will receive BRIUMVI4 as an intravenous (IV) infusion specifically for RMS treatment. The study includes participants who have not previously received BRIUMVI infusions before the study begins, allowing observation from the start of their treatment. This approach helps understand how the medication performs outside of controlled clinical trial settings. During the study, researchers will monitor participants for up to 96 weeks, measuring the annualized relapse rate (ARR) to evaluate disease activity. They will also track adverse events, serious adverse events, and infusion-related reactions at each infusion visit. Participants will undergo regular assessments to capture their health status and any side effects, providing a comprehensive view of treatment safety and patient experience over nearly two years.